Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Duragesic Recall Causes More Patch Woes for J&J
- Johnson & Johnson's PriCara unit is recalling two lots of its Duragesic fentanyl pain patch, according to the WSJ. The patch is used for opioid-tolerant patients who need round-the-clock pain relief. Fentanyl is also highly addictive. J&J's history of skin-patch-based medicine delivery systems is an unfortunate one: ...
- Blog posts 2009-01-02
Additional Resources
- J&J Loses 3rd Duragesic/Fentanyl Patch Death Case; $16.5 Mil. Verdict
- Johnson & Johnson units Janssen and ALZA have lost a third Duragesic patch death case. A jury in Chicago found J&J liable in the death of a Cicero, Ill., woman who had used a Duragesic to reduce the almost constant pain she experienced as a result of a neurological condition...
- Blog posts 2008-12-07
- Watson's Fentanyl Patch Recall Is 6th So Far; Why Don't Patches Work?
- Watson Pharmaceuticals has issued a recall for its fentanyl painkiller patch product, some of which have leaked. It's at least the sixth fentanyl patch recall since 1994. The recall again raises the question of whether fentanyl patches are too dangerous to be on the market. by Jim Edwards
- Blog posts 2009-08-10
- Following FDA Meeting BDSI Projects Submission of BEMA™ Fentanyl NDA In Second Quarter 2007
- MORRISVILLE, N.C. -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that, in light of, among other considerations, information gathered at a meeting with the FDA last week regarding the company's Phase III BEMATM Fentanyl product, the company is anticipating the submission of a New Drug Application NDA with the FDA on...
- Research articles 2006-09-20
- Pain Medicine Experts Available to Comment on Fentanyl.
- Byline: American Academy of Pain Medicine GLENVIEW, Ill., June 15 AScribe Newswire -- The American Academy of Pain Medicine today released the following media advisory. - - - - As heroin mixed with a powerful pain medication penetrates the ...
- Research articles 2006-06-15
- Redwood Toxicology Laboratory Expands Service Line; Announces New Lab Test For GHB "Date Rape Drug" & Fentanyl
- SANTA ROSA, Calif. -- Redwood Toxicology Laboratory, Inc. RTL now offers a new lab-based urine test for the detection of gamma hydroxybutyric acid GHB. GHB is typically associated with sexual assault or as a "date rape" drug due to its severe hypnotic and sedative effect at higher dosages. RTL...
- Research articles 2007-09-19
- J&J Q3: Duragesic Sales Down 20% Following Fentanyl Patch Death Warnings
- Doctors may finally be getting the message about dangers associated with fentanyl patches, if Johnson & Johnson's Q3 2009 earnings are any indication. While J&J saw revenues fall 5.3 percent to $15 billion and net income rise 22.2 percent to $3.3 billion, the numbers were much more dramatic on the...
- Blog posts 2009-10-14
- Noven Provides Update on Developmental Fentanyl Patch
- MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that the U.S. Food & Drug Administration ("FDA") has advised Noven that the FDA does not expect to approve Noven's Abbreviated New Drug Application ("ANDA") for a generic version of DuragesicR fentanyl transdermal system, and has ceased its review of the ANDA,...
- Research articles 2005-09-28
- BDSI Announces Significant Results in Phase III Clinical Trial Results for BEMA(TM) Fentanyl.
- M2 PRESSWIRE-25 April 2007-Headline Maker: BDSI Announces Significant Results in Phase III Clinical Trial Results for BEMATM FentanylC1994-2007 M2 COMMUNICATIONS LTD RDATE:25042007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step...
- Research articles 2007-04-25
- Wilco's Bennett Killed by Fentanyl; Is It Time to Tighten Rules on Patch Drugs?
- An Illinois coroner said Wilco songwriter Jay Bennett died of an accidental overdose from a fentanyl painkiller patch. The death should give the pharmaceutical industry pause to ask whether patch delivery systems should be subject to higher standards before being approved. by Jim Edwards
- Blog posts 2009-06-25
- Generics Threaten Drugmaker Cephalon's Success
- Biotechnology watchers are measuring success at Cephalon on how quickly the drugmaker can convert patients on its soon-to-go generic blockbuster Provigil to regular users of its narcoleptic successor Nuvigil. As Jim Edwards at BNET Pharma astutely pointed out exactly one year ago, however, competition also threatens to derail...
- Blog posts 2009-09-21
- Duragesic Recall Causes More Patch Woes for J&J
- Johnson & Johnson's PriCara unit is recalling two lots of its Duragesic fentanyl pain patch, according to the WSJ. The patch is used for opioid-tolerant patients who need round-the-clock pain relief. Fentanyl is also highly addictive. J&J's history of skin-patch-based medicine delivery systems is an unfortunate one: To give you...
- News items 2009-08-07
- Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?
- Shire SHPGY has voluntarily recalled the Daytrana ADHD patch citing problems with patients removing the liner on the back. It is not a safety issue, the company says. Daytrana is for children with ADHD; it is the only patch product to treat the condition. "Sudden death" is one of the...
- Blog posts 2009-12-07
- Generics makers keep new products coming
- [ILLUSTRATION OMITTED] WASHINGTON -- Actavis Group has been given approval to market a fentanyl transdermal system in the United States. Actavis' product is the generic equivalent of Duragesic (Alza Pharmaceuticals Inc./Janssen Pharmaceuticals LLP) and is available in 25-, 50-, 75- and 100-meg/hour strengths. Fentanyl transdermal system is indicated...
- Research articles 2007-09-17
- YM BIOSCIENCES INC. - FDA clearance for new trial.
- YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEFTM - YM to initiate trial in the U.S. and plans End of Phase II meeting with FDA - ...
- Research articles 2007-06-27
- Mylan Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you, sir. Operator Instructions. We will take our first question from Greg Gilbert with Merrill Lynch. Please go ahead. Greg Gilbert - Merrill Lynch Thanks. Good morning. My first one Ed, is on gross margin. Can you talk about some of the drivers that led to...
- Earnings calls 2008-10-30
- Mylan Technologies
- The FDA granted approval to Mylan Technologies for the first generic version of Alza's Duragesic Patch fentanyl transdermal system for the treatment of severe chronic pain that cannot be managed with alternate analgesics. When applied to the skin, the patch technology delivers fentanyl, an opioid pain medication absorbed into the...
- Research articles 2005-03-07
- How to Work With the Media in a Crisis Situation
- Bhopal. Exxon Valdez. DDT. Fentanyl. Sarin. Hydrochloric acid. LNG. These are words tied to chemicals that conjure up death and destruction resulting in a crisis. And a crisis means publicity. What often turns a chemical emergency into a crisis or disaster is surprise, compounded by confusion and errors that occur...
- White papers
- Court Dismisses Cygnus Lawsuit Against ALZA
- PALO ALTO, Calif.--BUSINESS WIRE--April 18, 1995--ALZA Corporation (NYSE:AZA) today announced that the U.S. District Court for the Northern District of California granted ALZA's motion to dismiss the lawsuit that Cygnus Therapeutic Systems brought against ALZA in January 1994 seeking a declaration of unenforceability and invalidity of an ALZA patent relating...
- Research articles 1995-04-18
- BEMA™ Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA
- BDSI's Pre-NDA Meeting with FDA goes according to plan and submission remains on track
- Research articles 2007-07-02
- << Previous
- page 1 of 1
- Next >>
Presented by American Express